LSL Pharma Group Past Earnings Performance
Past criteria checks 0/6
LSL Pharma Group's earnings have been declining at an average annual rate of -35.2%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 59.3% per year.
Key information
-35.2%
Earnings growth rate
-32.1%
EPS growth rate
| Personal Products Industry Growth | 35.8% |
| Revenue growth rate | 59.3% |
| Return on equity | -14.5% |
| Net Margin | -19.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How LSL Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 14 | -3 | 4 | 0 |
| 31 Mar 24 | 12 | -3 | 4 | 0 |
| 31 Dec 23 | 10 | -8 | 6 | 0 |
| 30 Sep 23 | 9 | -10 | 5 | 0 |
| 30 Jun 23 | 9 | -11 | 6 | 0 |
| 31 Mar 23 | 9 | -12 | 6 | 1 |
| 31 Dec 22 | 8 | -8 | 4 | 1 |
| 30 Sep 22 | 8 | -6 | 4 | 0 |
| 31 Dec 21 | 9 | -2 | 3 | 0 |
| 31 Dec 20 | 10 | 1 | 2 | 0 |
| 03 Oct 20 | 5 | 0 | 0 | 0 |
Quality Earnings: LSL is currently unprofitable.
Growing Profit Margin: LSL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LSL is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare LSL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LSL is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-5.2%).
Return on Equity
High ROE: LSL has a negative Return on Equity (-14.52%), as it is currently unprofitable.